Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.
Baker
Stephen J
SJ
Anacor Pharmaceuticals Inc., 1060 East Meadow Circle, Palo Alto, California 94303, USA. sbaker@anacor.com
Zhang
Yong-Kang
YK
Akama
Tsutomu
T
Lau
Agnes
A
Zhou
Huchen
H
Hernandez
Vincent
V
Mao
Weimin
W
Alley
M R K
MR
Sanders
Virginia
V
Plattner
Jacob J
JJ
D000287:Administration, Topical; D000935:Antifungal Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001232:Aspergillus fumigatus / Q000187:drug effects; D001896:Boron Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D002175:Candida / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D014009:Onychomycosis / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D014249:Trichophyton / Q000187:drug effects
D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; C512998:tavaborole